Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Pfizer is paying top dollar for a GLP-1 candidate from Fosun Pharma. Zealand Pharma penned a platform deal with brand new ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Yao Pharma's deal with the US pharmaceutical giant underscores China's growing role in global biotech licensing US ...

In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...

Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive investment.

Following the White House’s recent announcement of price reductions and expanded coverage for GLP-1 medications like Wegovy and Zepbound, many patients searching for obesity treatments are about to ...

Listen to more stories on the Noa app. “Ozempic is about to be old news,” my colleague Yasmin Tayag wrote in 2023, just before an even more powerful obesity drug, tirzepatide, then best known as ...

Eli Lilly and Co. this month rolled out plans to offer coverage of its popular obesity medications such as Zepbound through direct-to-employer arrangements set to begin in early 2026. The Indianapolis ...